Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / EP300



This biomarker is also known as:
  • p300 HAT,
  • KAT3B,
  • P300,
  • E1A-binding protein, 300kD,
  • p300,
  • E1A binding protein p300,
  • E1A-associated protein p300,
  • EC,
  • RSTS2,
  • histone acetyltransferase p300,

View in BioMuta


EP300, or E1A binding protein p300, functions as a histone acetyltransferase and regulates transcription via chromatin remodeling. EP300 is important in the processes of cell proliferation and differentiation, and also functions as acetyltransferase for nonhistone targets. EP300 mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: EP300


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

EP300 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.